Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. The couple says their ultimate goal is to develop new effective therapies for cancer. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. , 'Bal0891' 1 We are thrilled he is able to co-lead this new venture. My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. Shivaani Kummar - Professor of Medicine - Stanford - LinkedIn OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. Dive into the research topics where Shivaani Kummar is active. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed Expanding access to experimental cancer - Cancer Translated Want to join the faculty at the Knight Cancer Institute? Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Shivaani Kummar's Profile | Nature, The Lancet, Cancer Discovery People | OHSU Her research interests focus on developing novel therapies for cancer. 2022 ASCO Annual Meeting - Poster Session . Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . All these new agents have shown promising anticancer activity in laboratory testing and are now being evaluated in patients. 2001-2023 OHSU. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Palliative Care Administrative Assistant. Notice of Privacy Practices (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. shivaani kummar ohsu email These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. OHSU Foundation P.O. OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. Dr. Jody Kujovich, MD - Portland, OR | Oncology - Doximity Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. . BYLINE. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 Knight Cancer Institute Leaders | Knight Cancer Institute | OHSU We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. For help with all referral needs and questions, visit Referring Physicians. Professor of Medicine, OHSU. Clinical trials Drug development oncology. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. My patients. Shivaani Kummar. shivaani kummar ohsu email. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Stat4Onc Annual Symposium (2022) - University Of Connecticut Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. She also leads the division of hematology & medical oncology in the OHSU School of Medicine. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . Dr. Shivaani Kummar, Oncologist - FindaTopDoc Together they form a unique fingerprint. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . Abstracts & Presentations. Harnessing the predictive power of preclinical models for oncology drug It is a privilege to be able to work in this field. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. Accepting new patients Shivaani Kummar, MBBS, Portland, OR | Oncologist Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. Dr. Shivaani Kummar, MD, Medical Oncology Specialist - Portland, OR Recent external collaboration on country/territory level. Husband-wife team from Stanford University tapped to lead - OHSU News S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, Journal of Clinical Oncology 33 (30), 3409. What sort of projects are you working on right now? The provider is located at 3181 Sw Sam Jackson Park Rd Portland, Or 97239 and the phone number is (503) 314-7168 Which is Dr. Shivaani Kummar specialty? Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . Together they have built a strong record of discovery, innovation and care. Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. 2001-2022 Oregon Health & Science University. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography Administrative Coordinator, Denise Hopkins In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. OHSU is an equal opportunity affirmative action institution. Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid shivaani kummar ohsu email In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. Administrative Coordinator, Margaret Rogers

Electrical Competent Person Course, Michael Jackson Siblings Oldest To Youngest, Articles S